A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Search:
Medline
CancerConsultants.com
Both
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$43.21-1.42 (-3.18%)
NVS$40.12-1.18 (-2.86%)
SNY$29.7-0.64 (-2.11%)
GSK$34.85-1.19 (-3.3%)
Latest Clinical News
Preoperative PET-CT Reduces Number of Thoracotomies but Does Not Improve Survival of Patients with NSCLC (7/2/2009)
Researchers from Denmark have reported that “The use of PET-CT for preoperative staging of NSCLC [non–small cell lung cancer] reduced both the total number of thoracotomies and the number of futile thoracotomies but did not affect overall mortality.” The details of this study appeared in the July 2, 2009 issue of the New England Journal of Medicine.

CIN Associated with Long-term Risk of Recurrence and Invasive Cervical Cancer (7/2/2009)
Researchers from Canada have reported that women who have undergone treatment for cervical intraepithelial neoplasia (CIN) have a long-term increased risk of developing invasive carcinoma or a recurrence of CIN and, as such, need long-term surveillance. The details of this study appeared in the May 20, 2009 issue of the Journal of the National Cancer Institute.

More Cancer News
Featured Conference Coverage

ASCO 2008
May 30-June 2, 2008 - Chicago, IL

ASH 2008
December 6-9, 2008 - San Francisco, CA

SABCS 2008
December 10-14, 2008 - San Antonio, TX

A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists
March 9-12, 2008 - Tampa, FL

A report from the 2008 ASCO Genitourinary Cancers Symposium
February 14-16, 2008 - San Francisco, CA

 Targeting Angiogenesis in Glioblastoma Multiforme: Highlights and Clinical Implications from ASCO 2008
Physicians: up to 1.0 AMA PRA Category 1 Credit(s)TM.
Pharmacists up to 1.0 contact hour
Nurses up to 1.0 contact hour
Release Date: July 7, 2008
Expiration Date: July 6, 2009
This activity has been supported by an educational grant from Genentech BioOncology

 ASCO 2008: Updates in Bone Health Supportive Care Strategies
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

 Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2008
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

 Targeted Therapy and Genitourinary Malignancies: What You Need to Know from ASCO 2008
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

A Report from the 2008 Meeting of the American Society of Clinical Oncology

Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia
Dean Buckner, MD, Fred Hutchinson Cancer Research Center

Highlights of Treatment of Hematological Malignancies
Hagop Kantarjian, MD, The University of Texas, MD Anderson Cancer Center

Breast Cancer Update
Lee Schwartzberg, MD, FACP, Director of the West Clinic, Memphis, TN

The Evolving Role of EGFR Inhibitors in Colorectal Cancer
Jennifer Maxon


A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists

Updates in the Management of Gynecologic Cancers

A report from the 2008 ASCO Genitourinary Cancers Symposium

Updates in the Management of Prostate and Kidney Cancers - CME
Latest Legislative News
Latest FDA News
Sprycel® Gets Full Approval for Adults with Chronic Myeloid Leukemia (6/24/2009)
The U.S. Food and Drug Administration (FDA) has granted full approval to Bristol-Myers Squibb Company’s agent Sprycel® (dasatinib) for the treatment of adult patients in all phases of chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies including Gleevec® (imatinib mesylate).

Avastin® Approved for Progressive Glioblastoma (6/24/2009)
The U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) as a single agent for the treatment of glioblastoma that has progressed following prior therapy. The approval is based on objective response rates.

More FDA News News »
More FDA News

We Need Your Feedback
Click Here to Participate in Our Feedback Survey

Disease Centers

Additional Conference Coverage, CME, and News by Disease Type
Supportive Care Centers
Physician Resources
Scientific Advisors

© 1998-2007 CancerConsultants.com  All Rights Reserved.